TriSalus Life Sciences, Inc.

NASDAQ:TLSI

Medical - Devices

Healthcare
$2.45 +0.49%

+$0.02 today

Market cap
$151.16M
Beta
0.49
P/E (TTM)
-7.4
EPS (TTM)
-$0.53
52W Low $2.20High $7.95

Volume 0.40M

Average 0.38M

TLSI Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

TriSalus Life Sciences, Inc.NASDAQ: TLSI

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of $1.23M fell 17.7% year over year, behind the +44.8% change in trailing-twelve-month cost of revenue. Sequentially, it fell 30.2% from the prior quarter. Over 3 fiscal years it compounded at +45.6% a year.

Context

  • Cost of revenue amounted to 15.4% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -17.7% toward the trailing-twelve-month pace of +44.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.23M-30.2% QoQ
Last fiscal yearDec 2025
$6.97M+69.8% YoY
LTMMar 2026
$6.7M+44.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.7%——
1 year+69.8%——
3-year CAGR+45.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
6.97M USD
Year-over-year change
+69.8%
4-year CAGR
+55.4%

Cost of Revenue vs competitors

How TLSI compares with its peers on the latest reported figures

  • TLSI's LTM Mar 2026 cost of revenue of $6.7M is the 6th highest of the 11 companies compared; the peer median is $16.02M.
  • Its year-over-year change of +44.8% is the 3rd highest of 10, against a peer median of +17.1%.
  • Cost of revenue amounts to 14.9% of revenue for TLSI, versus a peer median of 50.6%.
TLSI Competitors Peer median
Cost of Revenue for TLSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STIMNeuronetics, Inc.LTM Mar 2026$78.91M +141.8%+70.6%52.0%
OWLTOwlet, Inc.LTM Mar 2026$52.61M +30.6%+4.4%49.1%
PREPrenetics Global LimitedLTM Mar 2026$47.41M +110.1%+65.9%41.7%
LNSRLENSAR, Inc.LTM Mar 2026$31.55M +5.2%+26.7%54.7%
NNOXNano-X Imaging Ltd.LTM Dec 2025$25.81M +17.4%+18.6%198.2%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$6.7M +44.8%+45.6%14.9%
MXCTMaxCyte, Inc.LTM Mar 2026$6.23M -13.4%+6.9%19.3%
PROFProfound Medical Corp.LTM Mar 2026$5.46M +17.1%+9.4%28.9%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$2.63M ——426.2%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.33M +13.5%-8.4%71.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$823K -40.6%-64.8%27.8%
Peer median (excluding TLSI) $16.02M+17.1%+9.4%50.6%

Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue8.4M12.4M18.51M29.43M45.15M
Cost of Revenue1.19M2.26M2.61M4.1M6.97M
Gross Profit7.21M10.14M15.91M25.33M38.19M
Gross Margin85.8%81.8%85.9%86.1%84.6%
Research & Development14.22M21.36M29.84M17.69M14.97M
Selling, General & Admin17.02M25.22M40.55M43.81M50.17M
Operating Expenses31.24M46.58M70.38M61.49M65.13M
Depreciation & Amortization464K414K684K744K626K
EBITDA(26.62M)(46.76M)(58.65M)(32.39M)(33.05M)
EBITDA Margin-316.8%-377.2%-316.9%-110.0%-73.2%
Operating Income(24.03M)(36.44M)(54.48M)(36.17M)(26.95M)
Operating Margin-286.1%-293.9%-294.3%-122.9%-59.7%
Interest Income0180K431K404K555K
Interest Expense1.76M1K16K3.09M5.54M
Other Income / Expenses(4.81M)(10.74M)(4.88M)6.13M(12.27M)
Income Before Tax(28.84M)(47.18M)(59.35M)(30.04M)(39.22M)
Pre-Tax Margin-343.3%-380.5%-320.6%-102.1%-86.9%
Income Tax Expense3K9K9K6K7K
Net Income(28.85M)(47.19M)(59.36M)(33.23M)(39.23M)
Net Margin-343.4%-380.6%-320.7%-112.9%-86.9%
EPS (Basic)(0.92)(1.59)(2.23)(1.25)(1.84)
EPS (Diluted)(0.92)(1.59)(2.23)(1.25)(1.84)
Weighted Avg Shares31.25M29.61M26.47M26.5M49.19M
Weighted Avg Shares (Diluted)31.25M29.61M26.47M26.5M37.9M

TriSalus Life Sciences, Inc.

NASDAQ:TLSI

Intrinsic Alpha fair value

Locked

Current Price

$2.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.